Year None202420232022202120202019 Apr 10, 2024 Arcutis Appoints David Topper as Chief Financial Officer Apr 05, 2024 Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Mar 28, 2024 Arcutis to Present at the 23rd Annual Needham Virtual Healthcare Conference Mar 11, 2024 Arcutis Promotes Todd Tucker to Chief Human Resources Officer Mar 10, 2024 Arcutis Presents Late-Breaking Data From INTEGUMENT-PED Phase 3 Trial of Roflumilast Cream 0.05% in Mar 09, 2024 New Research Reveals Genomic Profile of Seborrheic Dermatitis and Answers Key Questions on Immune Re Mar 05, 2024 Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Mar 04, 2024 Arcutis Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Op Mar 04, 2024 Arcutis Announces Acceptance of Late Breaking Abstract in Atopic Dermatitis Among Five New Topical R Current page 1 Page 2 Page 3 Next page next › Last page last » Displaying 1 - 9 of 21
